Rockwell SC, et al. Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative. J. Natl. Cancer Inst. 49: 735-749, 1972. PubMed: 4647494
Palom Y, et al. Structure of adduct X, the last unknown of the six major DNA adducts of mitomycin C formed in EMT6 mouse mammary tumor cells. Chem. Res. Toxicol. 13: 479-488, 2000. PubMed: 10858321
Collingridge DR, Rockwell S. Pentoxifylline improves the oxygenation and radiation response of BA1112 rat rhabdomyosarcomas and EMT6 mouse mammary carcinomas. Int. J. Cancer 90: 256-264, 2000. PubMed: 11091349
Rockwell S, Kelley M. RSR13, a synthetic allosteric modifier of hemoglobin, as an adjunct to radiotherapy: preliminary studies with EMT6 cells and tumors and normal tissues in mice. Radiat. Oncol. Investig. 6: 199-208, 1998. PubMed: 9822166
Rockwell S. In vivo-in vitro tumor systems: new models for studying the response of tumors to therapy. Lab. Anim. Sci. 27: 831-851, 1977. PubMed: 338981
Rockwell STumor-Cell SurvivalIn: Rockwell STumor models in cancer researchTotowa, New JerseyHumana Press Inc.617-631.
EMT6 was established from a transplantable murine mammary carcinoma that arose in a BALB/cCRGL mouse after implantation of a hyperplastic mammary alveolar nodule. The resulting tumor line (named KHJJ) was propagated in BALB/cKa mice and adapted to tissue culture after the 25th animal passage, and the cell line was named EMT. EMT6 is a clonal isolate of EMT isolated in 1971 at Stanford University. The EMT6 cell line can be grown either in animals as a tumor or in tissue culture. Cells derived from tumors have a reported in vitro plating efficiency of 30%. Cell grown in tissue culture reportedly have a plating efficiency of 70%.
|